Bortezomib
Trovati 9 articoli
- Multiple myeloma: stem cells make bone marrow cancer resistant to treatment
- Researchers at the Johns Hopkins Kimmel Cancer Center have shown that cancer stem cells for multiple myeloma share many properties with normal stem cells and have multiple ways of resisting chemotherapy and other treatments. A report on the evidence has been published in the journal Cancer Res... (Leggi Articolo)
- Lung cancer: Bortezomib extends survival 22 percent
- Results of the Southwest Oncology Group study, led by UC Davis Cancer Center researchers have shown that adding Bortezomib ( Velcade ) to a standard chemotherapy regimen of Gemcitabine and Carboplatin prolongs survival in patients with advanced non-small cell lung cancer. Patients taking Bort... (Leggi Articolo)
- Multiple myeloma: FDA has approved Velcade as second-line
- The FDA ( Food and Drug Administration ) approved a supplemental New Drug Application ( sNDA ) for Velcade ( Bortezomib ). This approval expands the label to include the treatment of patients with multiple myeloma who have received at least one prior therapy. Bortezomib is the first in a ne... (Leggi Articolo)
- Potential role of Bortezomib as frontline therapy in multiple myeloma
- Two phase II studies with Bortezomib ( Velcade ) showed very high response rates in front-line multiple myeloma. Overall response rates ranged from 88 to 95 percent with complete and near complete responses ranging from 25 to 29 percent. Use of Bortezomib in the front-line setting allowed for ... (Leggi Articolo)
- Multiple myeloma: NPI-0052, a compound from marine bacteria, appears effective
- An anti-cancer compound derived from bacteria dwelling in ocean-bottom sediments appears in laboratory tests to be a potent killer of drug-resistant multiple myeloma cells, and potentially with less toxicity than current treatments. The study is published in the Cancer Cell. The experiment... (Leggi Articolo)
- Relapsed or refractory B-cell non-Hodgkin's lymphoma: Velcade
- A phase II study, led by Andre Goy, of the University of Texas M.D. Anderson Cancer Center, Houston, evaluated efficacy and toxicity of Bortezomib ( Velcade ) in 60 patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. The patients were stratified into arm A ( mantle-cell lymphom... (Leggi Articolo)
- Europe: Velcade as a second-line treatment of multiple myeloma
- The European Commission has approved the use of Bortezomib ( Velcade ) for Injection as a second-line treatment in patients with multiple myeloma. Bortezomib is indicated as monotherapy for use in patients who have received at least one prior therapy and who have already undergone or are unsui... (Leggi Articolo)
- A combination with Bortezomib overcomes drug-resistant myeloma cells
- A novel strategy devised by Dana-Farber Cancer Institute scientists has proved highly effective in killing drug-resistant multiple myeloma cells in the laboratory. The researchers hope to move rapidly to clinical trials of the therapy, a combination of the drug Bortezomib ( Velcade ) and an ex... (Leggi Articolo)
- Bortezomib is superior to high-dose Dexamethasone in relapsed multiple myeloma
- The results from the phase III APEX study have been published in The New England Journal of Medicine. The study showed Velcade ( Bortezomib ) was superior in survival, time to disease progression, and response rates compared to standard of care, high-dose Dexamethasone, in patients with relapsed... (Leggi Articolo)
